Patents by Inventor Marlon D. Cowart
Marlon D. Cowart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200255423Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.Type: ApplicationFiled: October 16, 2019Publication date: August 13, 2020Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Ellen Yulin Tsai Chien, Marlon D. Cowart, Kristine E. Frank, Michael M. Friedman, David J. Hardee, J. Martin Herold, Huaqing Liu, Wei Qiu, Marc J. Scanio, Michael R. Schrimpf, Thomas R. Vargo, Stacy A. Van Epps, Matthew P. Webster, Andrew J. Little, Matthew H. Katcher, Theresa A. Dunstan, David A. Schiedler
-
Patent number: 10647717Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: GrantFiled: June 18, 2019Date of Patent: May 12, 2020Assignees: AbbVie S.á.r.l., Galapagos NVInventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck
-
Patent number: 10604515Abstract: The invention discloses compounds of Formula I, wherein X1, X2, R1, and R2 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.Type: GrantFiled: October 19, 2018Date of Patent: March 31, 2020Assignees: AbbVie S.á.r.l., Galapagos NVInventors: Robert J. Altenbach, Andrew Bogdan, Ghjuvanni Petru Diunisu Coti, Marlon D. Cowart, Stephen N. Greszler, Hans Kelgtermans, Philip R. Kym, Steven Emiel Van der Plas, Xueqing Wang
-
Patent number: 10508113Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, nad n are as defined herein, pharmaeceutical compositions 2C X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.Type: GrantFiled: March 12, 2019Date of Patent: December 17, 2019Assignee: AbbVie Inc.Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Ellen Yulin Tsai Chien, Marlon D. Cowart, Kristine E. Frank, Michael M. Friedman, David J. Hardee, J. Martin Herold, Huaqing Liu, Wei Qiu, Marc J. Scanio, Michael R. Schrimpf, Thomas R. Vargo, Stacy A. Van Epps, Matthew P. Webster, Andrew J. Little, Matthew H. Katcher
-
Publication number: 20190330207Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: June 18, 2019Publication date: October 31, 2019Inventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck
-
Publication number: 20190276450Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.Type: ApplicationFiled: March 12, 2019Publication date: September 12, 2019Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Ellen Yulin Tsai Chien, Marlon D. Cowart, Kristine E. Frank, Michael M. Friedman, David J. Hardee, J. Martin Herold, Huaqing Liu, Wei Qiu, Marc J. Scanio, Michael R. Schrimpf, Thomas R. Vargo, Stacy A. Van Epps, Matthew P. Webster, Andrew J. Little, Matthew H. Katcher
-
Publication number: 20190202823Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: March 6, 2019Publication date: July 4, 2019Inventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck
-
Publication number: 20190135827Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: January 8, 2019Publication date: May 9, 2019Inventors: Robert J. Altenbach, Andrew Bogdan, Marlon D. Cowart, William Rameshchandra Krishna Esmieu, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc J. Scanio, Xenia B. Searle, Eric Voight, Xueqing Wang, Ming C. Yeung
-
Patent number: 10259810Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: GrantFiled: December 15, 2017Date of Patent: April 16, 2019Assignees: AbbVie S.à.r.l., Galapagos NVInventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck
-
Publication number: 20190055229Abstract: The invention discloses compounds of Formula I, wherein X1, X2, R1, and R2 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.Type: ApplicationFiled: October 19, 2018Publication date: February 21, 2019Inventors: Robert J. Altenbach, Andrew Bogdan, Ghjuvanni Petru Diunisu Coti, Marlon D. Cowart, Stephen N. Greszler, Hans Kelgtermans, Philip R. Kym, Steven Emiel Van der Plas, Xueqing Wang
-
Patent number: 10138227Abstract: The invention discloses compounds of Formula I, wherein X1, X2, R1, and R2 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.Type: GrantFiled: May 23, 2017Date of Patent: November 27, 2018Assignees: AbbVie S.á.r.l., Galapagos NVInventors: Robert J. Altenbach, Andrew Bogdan, Ghjuvanni Petru Diunisu Coti, Marlon D. Cowart, Stephen N Greszler, Hans Kelgtermans, Philip R Kym, Steven Emiel Van der Plas, Xueqing Wang
-
Publication number: 20180334435Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.Type: ApplicationFiled: April 13, 2018Publication date: November 22, 2018Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
-
Patent number: 10130622Abstract: A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.Type: GrantFiled: October 7, 2016Date of Patent: November 20, 2018Assignees: AbbVie S.á.r.l., Galapagos NVInventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Katja E. Conrath, Douglas Cyr, Elsa De Lemos, Gert Jules Hector De Wilde, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Mathieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Chris Tse, Steven Emiel Van der Plas, Xueqing Wang
-
Publication number: 20180243298Abstract: A compound of Formula (I) having efficacy for the treatment or prevention of conditions and disorders related to TRPV3 activity, e.g. pain, atopic dermatitis, eczema, itch or psoriasis, is disclosed. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.Type: ApplicationFiled: March 30, 2016Publication date: August 30, 2018Inventors: Lawrence Black, Brian S. Brown, Bruce Clapham, Marlon D. Cowart, Michael J. Dart, Ramin Faghih, Jennifer Frost, Arthur R. Gomtsyan, Philip R. Kym, Huaqing Liu, Robert G. Schmidt, Lei Shi, Anurupa Shrestha, Kevin Sippy
-
Patent number: 10047051Abstract: The invention discloses compounds of Formula I wherein X, R1, R2, and R3 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.Type: GrantFiled: May 25, 2016Date of Patent: August 14, 2018Assignees: AbbVie S.á.r.l., Galapagos NVInventors: Robert J. Altenbach, Marlon D. Cowart, Tom Roger Lisette De Munck, Sébastien Jean Jacques Cédric Dropsit Montovert, Gregory A. Gfesser, Hans Kelgtermans, Sébastien Laurent Xavier Martina, Steven Emiel Van der Plas, Xueqing Wang
-
Patent number: 9969693Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav 1.7 and/or Nav 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.Type: GrantFiled: August 17, 2016Date of Patent: May 15, 2018Assignee: AbbVie Inc.Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
-
Publication number: 20180105522Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: December 15, 2017Publication date: April 19, 2018Inventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck
-
Patent number: 9890158Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: GrantFiled: October 7, 2016Date of Patent: February 13, 2018Assignees: AbbVie S.á.r.l., Galapagos NVInventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck
-
Publication number: 20180037587Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: October 17, 2017Publication date: February 8, 2018Inventors: Robert J. Altenbach, Andrew Bogdan, Marlon D. Cowart, William Rameshchandra Krishna Esmieu, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc J. Scanio, Xenia B. Searle, Eric Voight, Xeuqing Wang, Ming C. Yeung
-
Patent number: 9840513Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: GrantFiled: July 8, 2016Date of Patent: December 12, 2017Assignees: AbbVie S.á.r.l., Galapagos NVInventors: Robert J. Altenbach, Andrew Bogdan, Marlon D. Cowart, William Ramesh Esmieu, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc J. Scanio, Xenia B. Searle, Eric Voight, Xeuquing Wang, Ming C. Yeung